ClinicalTrials.gg
CompletedNCT02215252Updated May 5, 2017Results posted

A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN)

A Phase 2 interventional study of PF-05089771 150 mg and Matched placebo for PF-05089771 150 mg and pregabalin 300 mg in Diabetic Neuropathy, Painful, sponsored by Pfizer. Completed at 32 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-05-05.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
141
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing pregabalin in Diabetic Neuropathies — 1 open to participants now, 1 under way, 1 of them phase 3. Pregabalin · Diabetic Neuropathies.

Enrollment
13th of 17
141 · median 241
Started
2014
the only one that year
Phase 2
Only one
of the 17
Registered
16th of 17
by date
Lead sponsor
3 of 17
Pfizer

Among the 17 studies testing pregabalin in Diabetic Neuropathies, this one is the 13th largest by enrollment, is the only one that started in 2014, is the only one in phase 2, and was the 16th registered.

Diabetic Neuropathies

539 studies on the registry are indexed under Diabetic Neuropathies; 80 are open to participants now.

Browse Diabetic Neuropathies studies →

Open to participants now

1 of the 17 studies testing pregabalin in Diabetic Neuropathies is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 52 Diabetic Neuropathies studies recruiting now, 21 (40%) set no upper age limit and 24 (46%) stop at 75 or younger; 6 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing pregabalin in Diabetic Neuropathies, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of PF-05089771 as a monotherapy and as an add-on to pregabalin for the treatment of painful diabetic peripheral neuropathy (DPN)

03

Conditions studied

  • Diabetic Neuropathy, Painful

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 years to 80 years.
  • Diagnosis of Type 2 diabetes mellitlus (T2DM) with current glycosylated (HbA1c) levels of ≤ 11% at Screening and on a stable antidiabetic medication regimen for at least 30 days prior to randomization.
  • Presence of ongoing pain due to DPN for at least 6 months.
  • Willing to discontinue protocol-specified prohibited pain medications for DPN throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • Painful neuropathies or painful conditions other than DPN that may confound evaluation of pain due to DPN during the study.
  • Subjects who have failed previously on pregabalin (at the recommended label dose and for adequate duration) due to lack of efficacy.
  • Subjects with any medical or psychiatric conditions or clinically significant laboratory test abnormalities.
  • Pregnant women, lactating mothers, men with partners currently pregnant, women suspected of being pregnant, and women who wish to be pregnant during the course of the clinical study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
141 participants (actual)

Study arms

  • Experimental
    PF-05089771

    Drug: PF-05089771 150 mg

  • Experimental
    Placebo

    Drug: Matched placebo for PF-05089771 150 mg and pregabalin 300 mg

  • Experimental
    Pregabalin

    Drug: Pregabalin 300 mg

  • Experimental
    PF-05089771 + Pregabalin

    Drug: PF-05089771 150 mg + Pregabalin 300 mg

Interventions

  • PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.

  • DrugMatched placebo for PF-05089771 150 mg and pregabalin 300 mg

    Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.

  • Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.

  • DrugPF-05089771 150 mg + Pregabalin 300 mg

    Drug page: PF-05089771

    PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.

06

What researchers measure

Primary outcomes

  1. Daily Pain Numeric Rating Scale (NRS)

    The endpoint average pain score, based on the mean of the last 7 days' daily pain numeric rating scale (NRS) scores at (NRS is an 11-point scale where 0 = no pain and 10 = worst possible pain) from the daily pain diaries while receiving study medication during the treatment period.

    Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4

Secondary outcomes

  1. Responder Rate Based on a 30% Improvement in Mean Pain Response Using the Daily Pain NRS Score

    Percentage of participants that received ≥30% improvement from baseline in mean pain response (from the daily pain diary).

    Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4

  2. Responder Rate Based on a 50% Improvement in Mean Pain Response Using the Daily Pain NRS Score

    Percentage of participants that received ≥50% improvement from baseline in mean pain response (from the daily pain diary).

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  3. Neuropathic Pain Symptom Inventory (NPSI) - Burning (Superficial) Spontaneous Pain

    Participants rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

    Time frame: Baseline, Week 2, and Week 4

  4. Neuropathic Pain Symptom Inventory (NPSI) - Pressing (Deep) Spontaneous Pain

    Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

    Time frame: Baseline, Week 2 and Week 4

  5. Neuropathic Pain Symptom Inventory (NPSI) - Paroxysmal Pain

    Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

    Time frame: Baseline, Week 2, and Week 4

  6. Neuropathic Pain Symptom Inventory (NPSI) - Evoked Pain

    Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

    Time frame: Baseline, Week 2 and Week 4

  7. Neuropathic Pain Symptom Inventory (NPSI) - Paresthesia/Dysethesia

    Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

    Time frame: Baseline, Week 2 and Week 4

  8. Neuropathic Pain Symptom Inventory (NPSI) - Total Score

    Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

    Time frame: Baseline, Week 2 and Week 4

  9. Patient's Global Impression of Change Score (PGIC).

    Participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse) at week 4. The PGIC was combined to produce a 3-point scale, "Improved", "No Change" and "Worse".

    Time frame: Baseline, Week 2, and Week 4

  10. Daily Sleep Interference Scale Score (DSIS).

    Participant rated 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication. This score was measured as a weekly average.

    Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4

  11. Total Amount of Rescue Medication Per Week

    Total amount of rescue medication participants take per week

    Time frame: Baseline, Week 1, Week 2, Week 3, and Week 4

  12. Number of Days Participants Take Rescue Medication

    Number of days participants take rescue medication per week.

    Time frame: Baseline, Week 1, Week 2, Week 3 and Week 4

  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to Adverse Events (AEs)

    An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect.

    Time frame: Screening to Day 36, and Day 64

  14. Number of Participants With Laboratory Test Values of Potential Clinical Importance

    The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests.

    Time frame: Screening, Day 1, Day 15 and Day 29

  15. Fasted Total Cholesterol Values

    Percentage Change from Baseline in Fasted Total Cholesterol values

    Time frame: Baseline, Week 2 and Week 4

  16. Fasted Low Density Lipoprotein (LDL) Cholesterol

    Percentage Change from Baseline in LDL cholesterol Friedewald by PEG

    Time frame: Baseline, Week 2 and Week 4

  17. Plasma Concentration of PF-05089771

    All participants in this group were analysed. Only plasma PK concentration of PF-05089771 was analysed.

    Time frame: Baseline, Week 2 and Week 4

07

Results

Posted May 5, 2017

Participant flow

Eligibility included healthy male and/or female participants of non childbearing potential between the ages of 18 and 80 years, inclusive, and a diagnosis of painful diabetic peripheral neuropathy and type II diabetes. Following the interim analysis, the study was stopped. No participants were dosed with PF-05089771 150mg BID + pregabalin.

Participant flow — Overall Study
MilestonePF-05089771 150 mg BIDPregabalinPlacebo
Started444645
Completed423841
Not completed284
Withdrew: Adverse event152
Withdrew: Lost to follow-up001
Withdrew: Does not meet entrance criteria010
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject100
Withdrew: Other011

Outcome measures

PrimaryDaily Pain Numeric Rating Scale (NRS)

The endpoint average pain score, based on the mean of the last 7 days' daily pain numeric rating scale (NRS) scores at (NRS is an 11-point scale where 0 = no pain and 10 = worst possible pain) from the daily pain diaries while receiving study medication during the treatment period.

Time frame:
Baseline, Week 1, Week 2, Week 3 and Week 4
Reported as:
Mean · Unit on a scale
Daily Pain Numeric Rating Scale (NRS)
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)6.17 ± 1.1646.62 ± 1.4206.35 ± 1.170
Week 1 (n = 44, 46, 44)5.45 ± 1.3725.87 ± 1.8726.07 ± 1.454
Week 2 (n = 43, 44, 40)5.14 ± 1.7625.26 ± 2.3026.10 ± 1.504
Week 3 (n = 38, 40, 41)5.01 ± 1.8205.36 ± 2.3865.76 ± 1.540
Week 4 (n = 41, 38, 39)4.83 ± 1.5955.14 ± 2.5085.61 ± 1.820
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -0.41 · 90% CI -1.00 to 0.17
  • Pregabalin vs Placebo · Mean difference (final values): -0.53 · 90% CI -0.91 to -0.20
SecondaryResponder Rate Based on a 30% Improvement in Mean Pain Response Using the Daily Pain NRS Score

Percentage of participants that received ≥30% improvement from baseline in mean pain response (from the daily pain diary).

Time frame:
Baseline, Week 1, Week 2, Week 3 and Week 4
Reported as:
Number · Percentage of participants
Responder Rate Based on a 30% Improvement in Mean Pain Response Using the Daily Pain NRS Score
Percentage of participantsPF-05089771 150 mg BIDPregabalinPlacebo
Week 1 (n = 44, 46, 45)9.0915.224.44
Week 2 (n = 44, 45, 44)22.7331.119.09
Week 3 (n = 42, 42, 43)23.8126.1911.63
Week 4 (n = 42, 38, 43)28.5731.5816.28
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Odds ratio (or): 1.91 · 90% CI 0.78 to 4.69
  • Pregabalin vs Placebo · Odds ratio (or): 2.63 · 90% CI 1.06 to 6.56
SecondaryResponder Rate Based on a 50% Improvement in Mean Pain Response Using the Daily Pain NRS Score

Percentage of participants that received ≥50% improvement from baseline in mean pain response (from the daily pain diary).

Time frame:
Baseline, Week 1, Week 2, Week 3, and Week 4
Reported as:
Number · Percentage of participants
Responder Rate Based on a 50% Improvement in Mean Pain Response Using the Daily Pain NRS Score
Percentage of participantsPF-05089771 150 mg BIDPregabalinPlacebo
Week 1 (n = 44, 46, 45)04.354.44
Week 2 (n = 44, 45, 44)11.3615.562.27
Week 3 (n = 42, 42, 43)7.1419.052.33
Week 4 (n = 42, 38, 43)9.5223.686.98
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Odds ratio (or): 1.25 · 90% CI 0.33 to 4.74
  • Pregabalin vs Placebo · Odds ratio (or): 4.75 · 90% CI 1.43 to 15.81
SecondaryNeuropathic Pain Symptom Inventory (NPSI) - Burning (Superficial) Spontaneous Pain

Participants rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

Time frame:
Baseline, Week 2, and Week 4
Reported as:
Mean · Unit on a scale
Neuropathic Pain Symptom Inventory (NPSI) - Burning (Superficial) Spontaneous Pain
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)4.6 ± 2.715.3 ± 2.494.8 ± 2.35
Week 2 (n = 42, 41, 43)3.7 ± 2.944.3 ± 3.064.2 ± 2.35
Week 4 (n = 42, 38, 42)3.4 ± 3.044.3 ± 2.804.5 ± 2.55
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -1.04 · 90% CI -1.75 to -0.32
  • Pregabalin vs Placebo · Mean difference (final values): -0.69 · 90% CI -1.43 to 0.04
SecondaryNeuropathic Pain Symptom Inventory (NPSI) - Pressing (Deep) Spontaneous Pain

Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · Unit on a scale
Neuropathic Pain Symptom Inventory (NPSI) - Pressing (Deep) Spontaneous Pain
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)3.8 ± 2.484.9 ± 2.214.5 ± 2.40
Week 2 (n = 42, 41, 43)3.3 ± 2.514.4 ± 2.834.2 ± 2.33
Week 4 (n = 42, 38, 42)3.4 ± 2.673.9 ± 3.084.0 ± 2.48
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -0.22 · 90% CI -0.86 to 0.43
  • Pregabalin vs Placebo · Mean difference (final values): -0.66 · 90% CI -1.33 to 0.00
SecondaryNeuropathic Pain Symptom Inventory (NPSI) - Paroxysmal Pain

Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

Time frame:
Baseline, Week 2, and Week 4
Reported as:
Mean · Unit on a scale
Neuropathic Pain Symptom Inventory (NPSI) - Paroxysmal Pain
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)4.5 ± 2.365.8 ± 2.185.6 ± 2.23
Week 2 (n = 42, 41, 43)4.1 ± 2.614.7 ± 2.984.9 ± 2.11
Week 4 (n = 42, 38, 42)3.9 ± 2.874.6 ± 2.834.8 ± 2.55
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -0.10 · 90% CI -0.87 to 0.67
  • Pregabalin vs Placebo · Mean difference (final values): -0.58 · 90% CI -1.36 to 0.20
SecondaryNeuropathic Pain Symptom Inventory (NPSI) - Evoked Pain

Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · Unit on a scale
Neuropathic Pain Symptom Inventory (NPSI) - Evoked Pain
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 45, 45)2.7 ± 2.385.0 ± 2.514.2 ± 2.42
Week 2 (n = 42, 40, 43)2.0 ± 1.924.0 ± 2.673.5 ± 2.47
Week 4 (n = 42, 37, 42)2.3 ± 2.243.8 ± 3.073.6 ± 2.53
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): 0.09 · 90% CI -0.49 to 0.67
  • Pregabalin vs Placebo · Mean difference (final values): -0.46 · 90% CI -1.05 to 0.13
SecondaryNeuropathic Pain Symptom Inventory (NPSI) - Paresthesia/Dysethesia

Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · Unit on a scale
Neuropathic Pain Symptom Inventory (NPSI) - Paresthesia/Dysethesia
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)5.7 ± 2.026.1 ± 2.356.6 ± 1.96
Week 2 (n = 42, 41, 43)4.8 ± 2.455.3 ± 2.835.9 ± 2.40
Week 4 (n = 42, 38, 42)4.9 ± 2.345.4 ± 2.845.9 ± 2.63
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -0.35 · 90% CI -1.09 to 0.39
  • Pregabalin vs Placebo · Mean difference (final values): -0.24 · 90% CI -1.00 to 0.51
SecondaryNeuropathic Pain Symptom Inventory (NPSI) - Total Score

Participant rated questionnaire to evaluate different symptoms of neuropathic pain (dimensions: burning \[superficial\] spontaneous pain, pressing \[deep\] spontaneous pain, paroxysmal pain, evoked pain, and paresthesia/dyesthesia \[P/D\]) including 10 descriptors quantified on a 0 (no symptoms) to 10 (worst symptoms imaginable) and 2 temporal items assessing duration of spontaneous ongoing and paroxysmal pain. A score in each dimension and also a total score (from 0-100) is generated using data from the questionnaire. Higher score indicates a greater intensity of pain.

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · Unit on a scale
Neuropathic Pain Symptom Inventory (NPSI) - Total Score
Unit on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 45, 45)40.6 ± 17.3353.4 ± 19.3550.7 ± 16.87
Week 2 (n = 42, 40, 34)34.2 ± 17.3944.6 ± 24.6444.7 ± 18.11
Week 4 (n = 42, 37, 42)34.7 ± 19.4042.7 ± 27.2344.5 ± 20.18
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -0.27 · 90% CI -5.12 to 4.57
  • Pregabalin vs Placebo · Mean difference (final values): -5.61 · 90% CI -10.57 to -0.66
SecondaryPatient's Global Impression of Change Score (PGIC).

Participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse) at week 4. The PGIC was combined to produce a 3-point scale, "Improved", "No Change" and "Worse".

Time frame:
Baseline, Week 2, and Week 4
Reported as:
Number · Number of participants
Patient's Global Impression of Change Score (PGIC).
Number of participantsPF-05089771 150 mg BIDPregabalinPlacebo
Improved (Baseline, n = 43, 46, 45)201116
Improved (Week 2, n = 42, 41, 43)273026
Improved (Week 4, n = 42, 38, 42)282724
No change (Baseline, n = 43, 46, 45)193025
No change (Week 2, n = 42, 41, 43)10713
No change (Week 4, n = 42, 38, 42)12914
Worse (Baseline, n = 43, 46, 35)454
Worse (Week 2, n = 42, 41, 43)544
Worse (Week 4, n = 42, 38, 42)224
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Odds ratio (or): 0.70 · 90% CI 0.34 to 1.45
  • Pregabalin vs Placebo · Odds ratio (or): 0.50 · 90% CI 0.24 to 1.07
SecondaryDaily Sleep Interference Scale Score (DSIS).

Participant rated 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Self-assessment performed daily on awakening prior to taking study medication. This score was measured as a weekly average.

Time frame:
Baseline, Week 1, Week 2, Week 3 and Week 4
Reported as:
Mean · number on a scale
Daily Sleep Interference Scale Score (DSIS).
number on a scalePF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)4.7 ± 2.425.6 ± 2.384.9 ± 2.29
Week 1 (n= 44, 46, 44)4.1 ± 2.294.7 ± 2.554.7 ± 2.46
Week 2 (n = 43, 44, 40)4.0 ± 2.334.1 ± 2.744.7 ± 2.41
Week 3 (n = 38, 40, 41)3.6 ± 2.284.4 ± 2.714.3 ± 2.49
Week 4 (n = 41, 38, 39)3.4 ± 2.134.2 ± 2.824.3 ± 2.51
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): -0.59 · 90% CI -1.16 to -0.02
  • Pregabalin vs Placebo · Mean difference (final values): -1.00 · 90% CI -1.57 to -0.43
SecondaryTotal Amount of Rescue Medication Per Week

Total amount of rescue medication participants take per week

Time frame:
Baseline, Week 1, Week 2, Week 3, and Week 4
Reported as:
Mean · mg
Total Amount of Rescue Medication Per Week
mgPF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)2726 ± 43103398 ± 57231863 ± 3684
Week 1 (n = 44, 46, 45)2272 ± 40432897 ± 56051694 ± 3425
Week 2 (n = 44, 45, 44)1669 ± 32482952 ± 54881391 ± 3238
Week 3 (n = 42, 42, 43)1851 ± 32281885 ± 49181306 ± 3308
Week 4 (n = 42, 38, 43)1617 ± 29452328 ± 52561372 ± 3307
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): 192 · 90% CI -1161 to 1544
  • Pregabalin vs Placebo · Mean difference (final values): 611 · 90% CI -735 to 1956
SecondaryNumber of Days Participants Take Rescue Medication

Number of days participants take rescue medication per week.

Time frame:
Baseline, Week 1, Week 2, Week 3 and Week 4
Reported as:
Mean · days
Number of Days Participants Take Rescue Medication
daysPF-05089771 150 mg BIDPregabalinPlacebo
Baseline (n = 44, 46, 45)2.8 ± 3.492.1 ± 3.021.6 ± 2.60
Week 1 (n = 44, 46, 45)2.3 ± 3.161.8 ± 2.741.5 ± 2.50
Week 2 (n = 44, 45, 44)2.0 ± 3.081.7 ± 2.631.2 ± 2.25
Week 3 (n = 42, 42, 43)2.1 ± 3.001.2 ± 2.351.0 ± 2.10
Week 4 (n = 42, 38, 43)1.9 ± 2.801.6 ± 2.551.1 ± 2.28
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to Adverse Events (AEs)

An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; life threatening (immediate risk of death); initial or prolonged inpatient hospitalization; persistent or significant disability/incapacity; resulted in congenital anomaly/birth defect.

Time frame:
Screening to Day 36, and Day 64
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to Adverse Events (AEs)
ParticipantsPF-05089771 150 mg BIDPregabalinPlacebo
Participants with TEAEs162417
Participants with SAE110
Withdrawals due to AEs152
SecondaryNumber of Participants With Laboratory Test Values of Potential Clinical Importance

The total number of participants with laboratory test abnormalities (without regard to baseline abnormality) was assessed. Clinical laboratory tests included hematology, chemistry, urinalysis and some other tests.

Time frame:
Screening, Day 1, Day 15 and Day 29
Reported as:
Number · Participants
Number of Participants With Laboratory Test Values of Potential Clinical Importance
ParticipantsPF-05089771 150 mg BIDPregabalinPlacebo
Number of Participants With Laboratory Test Values of Potential Clinical Importance383537
SecondaryFasted Total Cholesterol Values

Percentage Change from Baseline in Fasted Total Cholesterol values

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · Percent change
Fasted Total Cholesterol Values
Percent changePF-05089771 150 mg BIDPregabalinPlacebo
Week 2 (n = 41, 37, 41)3.46 ± 12.279-1.45 ± 10.242-0.43 ± 14.271
Week 4 (n = 40, 33, 39)6.59 ± 15.618-0.11 ± 10.023-1.71 ± 14.242
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): 7.99 · 90% CI 2.98 to 13.01
  • Pregabalin vs Placebo · Mean difference (final values): 0.75 · 90% CI -4.46 to 5.95
SecondaryFasted Low Density Lipoprotein (LDL) Cholesterol

Percentage Change from Baseline in LDL cholesterol Friedewald by PEG

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · Perecent change
Fasted Low Density Lipoprotein (LDL) Cholesterol
Perecent changePF-05089771 150 mg BIDPregabalinPlacebo
Week 2 (n = 38, 34, 39)8.17 ± 23.849-1.73 ± 14.4960.81 ± 22.900
Week 4 (n = 37, 31, 36)13.61 ± 29.7290.85 ± 13.5121.48 ± 19.804
Statistical analysis
  • PF-05089771 150 mg BID vs Placebo · Mean difference (final values): 11.55 · 90% CI 2.94 to 20.17
  • Pregabalin vs Placebo · Mean difference (final values): -2.42 · 90% CI -11.38 to 6.54
SecondaryPlasma Concentration of PF-05089771

All participants in this group were analysed. Only plasma PK concentration of PF-05089771 was analysed.

Time frame:
Baseline, Week 2 and Week 4
Reported as:
Mean · ng/ml
Plasma Concentration of PF-05089771
ng/mlPF-05089771 150 mg BID
Baseline (n = 43)NA ± NA
Week 2 (n = 41)7673 ± 4861
Week 4 (n = 41)8784 ± 5749

Adverse events

Collected over From first dose of placebo run-in until 28 days after last dose of placebo run-out, an average of 3 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PF-05089771 150 mg BID—1/44 (2.3%)3/44 (6.8%)
Pregabalin—1/46 (2.2%)12/46 (26.1%)
Placebo—0/45 (0%)10/45 (22.2%)
Most frequent serious events
Most frequent serious events
EventPF-05089771 150 mg BIDPregabalinPlacebo
PneumoniaInfections and infestations1/440/460/45
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/440/460/45
Cardiac failure congestiveCardiac disorders0/441/460/45
Most frequent other events
Most frequent other events
EventPF-05089771 150 mg BIDPregabalinPlacebo
DizzinessNervous system disorders0/445/462/45
HeadacheNervous system disorders2/443/464/45
Upper respiratory tract infectionInfections and infestations1/441/463/45
NauseaGastrointestinal disorders0/443/461/45
Vulvovaginal pruritusReproductive system and breast disorders0/171/190/14

Baseline characteristics

The safety analysis set consisted of all participants who received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)PF-05089771 150 mg BIDPregabalinPlaceboTotal
Mean59.3 ± 9.458.1 ± 11.359.2 ± 10.958.9 ± 10.5
Sex: Female, Male
Sex: Female, Male(Participants)PF-05089771 150 mg BIDPregabalinPlaceboTotal
Female17191450
Male27273185
08

Study locations

32 sites
  • Clinical Research Consortium Arizona
    Phoenix, Arizona 85003, United States
  • Arizona Research Center
    Phoenix, Arizona 85023, United States
  • Neuro-Pain Medical Center
    Fresno, California 93710, United States
  • Meridien Research
    Bradenton, Florida 34208, United States
  • PAB Clinical Research
    Brandon, Florida 33511, United States
  • Pulmonary Associates of Brandon (PAB)
    Brandon, Florida 33511, United States
  • Meridien Research
    Brooksville, Florida 34601, United States
  • Clinical Physiology Associates
    Fort Myers, Florida 33912, United States
  • MD Clinical
    Hallandale, Florida 33009, United States
  • Meridien Research
    Lakeland, Florida 33805, United States
  • Family Care Specialists
    Ocala, Florida 34471, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Oviedo Medical Research, LLC
    Oviedo, Florida 32765, United States
  • Meridien Research
    St. Petersburg, Florida 33709, United States
  • Meridien Research
    Tampa, Florida 33634, United States
  • Metabolic Research Institute, Inc
    West Palm Beach, Florida 33401, United States
  • Columbus Regional Research Institute
    Columbus, Georgia 31904, United States
  • Clinical Research Advantage, Inc
    Evansville, Indiana 47714, United States
  • Brigham and Women's Hospital
    Boston, Massachusetts 02115, United States
  • Novex Clinical Research, LLC
    New Bedford, Massachusetts 02740, United States
  • Beacon Clinical Research, LLC
    Quincy, Massachusetts 02169, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Clinical Research Consortium
    Las Vegas, Nevada 89119, United States
  • The Medical Research Network, LLC
    New York, New York 10128, United States
  • New Phase Research and Development
    Knoxville, Tennessee 37919, United States
  • Internal Medicine Associates
    Tullahoma, Tennessee 37388, United States
  • Trinity Clinical Research, LLC
    Tullahoma, Tennessee 37388, United States
  • KRK Medical Research
    Arlington, Texas 76012, United States
  • Nerve and Muscle Center of Texas
    Houston, Texas 77030, United States
  • National Clinical Research - Norfolk, Inc
    Norfolk, Virginia 23502, United States
  • Eastern Virginia Medical School
    Norfolk, Virginia 23510, United States
  • Rainier Clinical Research Center, Inc
    Renton, Washington 98057, United States
09

References and documents

Individual participant data

Plan to share: Yes — Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Jul 2015, 8 months.

Results were first posted in May 2017, 1 year 9 months after primary completion.

Of 25 phase 2 interventional studies under Diabetic Neuropathies, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 35. This study's 8 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2014
First posted
Aug 13, 2014
StartActual
Nov 10, 2014
Primary completionActual
Jul 15, 2015
CompletionActual
Sep 28, 2015
Results first posted
May 5, 2017
Last update
May 5, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02215252
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 13, 2014
Start date
Nov 10, 2014
Primary completion
Jul 15, 2015
Completion
Sep 28, 2015
Results posted
May 5, 2017
Last update
May 5, 2017

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PF-05089771 · Pregabalin

Start the discussion